18 May 2021Ended

Avoiding hurdles in molecular assay development


Estimated Turnout

upto 100
Based on previous editions


May 2021


Not Available
Claim event to edit details

Naeem Nathoo holds a Master’s degree in Biology and Microbiology from Western University in London, Ontario. Naeem joined Thermo Fisher Scientific .. Read more in 2016 and is currently the Business Development Manager for the Molecular Diagnostics, Commercial Supply, and OEM businesses. Naeem has extensive experience in B2B partnerships with bio-incubators, and his deep understanding of developing partnerships for the research, development and validation, and ultimately commercialization phases of the molecular diagnostic journey allow for time savings and operational efficiency. The global pandemic has increased focus and scrutiny on molecular diagnostic assay development, resulting in a need for assays that provide quick results while delivering expected performance and quality. The need for these types of assays in infectious disease diagnostics has become apparent on a wide scale, but molecular diagnostic testing is also poised to grow in other areas such as genetic testing, prenatal testing, oncology, and pharmacogenomics over the next several years. This webinar will demonstrate how small changes to assay components (such as enzyme selection) can overcome many of these hurdles during development and significantly impact the overall quality and accuracy of an assay. The presentation will cover specific cases related to SARS-CoV-2 detection, and highlight quality and manufacturing considerations crucial to development of a molecular assay for any target.

  • Share your Experience
  • Organizer
Logo Follow Company


USA276 Total Events / 25 Upcoming Events

More Events From The Organizer

You have no contacts. Please add contacts from below or share on social media

Send to all
No Results